Syphilis OTC Test Developer NOWDiagnostics Raises $22.5M

 
• By Ryan Nelson

The Series B funding round led by DigitalDx Ventures will support development and commercialization of more than 30 rapid diagnostic tests in NOWDx’s clinical research pipeline, including its First To Know Syphilis OTC test, currently under US FDA De Novo review, which provides at-home results in minutes.

NOWDx entered a de novo classification request to the US FDA for its Syphilis OTC test in January. • Source: Shutterstock

More from United States

More from North America